Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Amplia Therapeutics Ltd. reported promising results from its ongoing Phase 2a ACCENT trial, where its drug narmafotinib showed a higher objective response rate and longer patient time on trial compared to historical data in treating advanced pancreatic cancer. The trial has seen nine confirmed partial responses among the initial patients and is advancing ahead of schedule in recruitment. This progress highlights potential efficacy and tolerability of narmafotinib when combined with standard chemotherapy treatments.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
